Anti-B7-H4 Antibodies and Immunoconjugates

Patent metadata

Field	Value
Publication number	US-2025297011-A1
Application number	US-202519081781-A
Country	US
Kind code	A1
Filing date	Mar 17, 2025
Priority date	Sep 12, 2014
Publication date	Sep 25, 2025
Grant date	—

Abstract

The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.

First claim

1 . An isolated antibody that binds to B7-H4, wherein the antibody comprises:
(i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 39, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 40, (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 41, (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 42, (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 43, and (vi) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 129.

2 . (canceled)

3 . The antibody of claim 1 , further comprising a heavy chain framework FR3 sequence of SEQ ID NO: 53.

4 . (canceled)

5 . The antibody of claim 1 , comprising a light chain framework FR3 sequence of SEQ ID NO: 47.

6 . (canceled)

7 . The antibody of claim 1 , comprising a VH sequence of SEQ ID NO: 38.

8 . The antibody of claim 1 , comprising a VL sequence of SEQ ID NO: 126.

9 . An isolated antibody that binds to B7-H4, wherein the antibody comprises (a) a VH sequence of SEQ ID NO: 38 and a VL sequence of SEQ ID NO: 126; or (b) a VH sequence of SEQ ID NO: 127 and a VL sequence of SEQ ID NO: 126.

10 . An isolated antibody that binds to B7-H4, wherein the antibody comprises:
(i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 39, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 40, (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 128, (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 42, (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 43, and (vi) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 129.

11 . The antibody of claim 1 , which is a monoclonal antibody.

12 . The antibody of claim 1 , which is a human, humanized, or chimeric antibody.

13 . The antibody of claim 1 , which is an antibody fragment that binds B7-H4.

14 . The antibody of claim 1 , which is an IgG1, IgG2a or IgG2b antibody.

15 . The antibody of claim 1 , wherein the antibody comprises one or more engineered cysteine amino acids residues.

16 . The antibody of claim 15 , wherein the one or more engineered cysteine amino acid residues is located in the light chain.

17 . The antibody of claim 15 , wherein the one or more engineered cysteine amino acid residues is located in the heavy chain.

18 . The antibody of claim 17 , wherein the antibody comprises at least one mutation in the heavy chain constant region selected from A118C and S400C.

19 . The antibody of claim 16 , wherein the antibody comprises at least one mutation in the light chain constant region selected from K149C and V205C.

20 . An isolated antibody that binds to B7-H4, wherein the antibody comprises (a) a heavy chain sequence of SEQ ID NO: 132 and a light chain sequence of SEQ ID NO: 134; or (b) a heavy chain sequence of SEQ ID NO: 133 and a light chain sequence of SEQ ID NO: 134; or (c) a heavy chain sequence of SEQ ID NO: 130 and a light chain sequence of SEQ ID NO: 140; or (d) a heavy chain sequence of SEQ ID NO: 130 and a light chain sequence of SEQ ID NO: 141; or (e) a heavy chain sequence of SEQ ID NO: 131 and a light chain sequence of SEQ ID NO: 140; or (f) a heavy chain sequence of SEQ ID NO: 131 and a light chain sequence of 141; or (g) a heavy chain sequence of SEQ ID NO: 144 and a light chain sequence of SEQ ID NO: 142; or (h) a heavy chain sequence of SEQ ID NO: 144 and a light chain sequence of SEQ ID NO: 143; or (i) a heavy chain sequence of SEQ ID NO: 137 and a light chain sequence of SEQ ID NO: 138; or (j) a heavy chain sequence of SEQ ID NO: 130 and a light chain sequence of SEQ ID NO: 145; or (d) a heavy chain sequence of SEQ ID NO: 130 and a light chain sequence of SEQ ID NO: 146; or (e) a heavy chain sequence of SEQ ID NO: 131 and a light chain sequence of SEQ ID NO: 145; or (f) a heavy chain sequence of SEQ ID NO: 131 and a light chain sequence of 146; or (g) a heavy chain sequence of SEQ ID NO: 144 and a light chain sequence of SEQ ID NO: 147; or (h) a heavy chain sequence of SEQ ID NO: 144 and a light chain sequence of SEQ ID NO: 148.

21 - 44 . (canceled)

45 . Isolated nucleic acid encoding
the antibody of claim 1 .

46 . A host cell comprising the nucleic acid of claim 45 .

47 . A method of producing an antibody comprising culturing the host cell of claim 45 so that the antibody or half antibody is produced.

48 - 100 . (canceled)

Assignees

• Genentech Inc

Inventors

• Leong Steven R
• Polson Andrew
• Polakis Paul
• Wu Yan
• Liang Wei-Ching
• Firestein Ron

Classifications

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• C07K2317/567

  Framework region [FR] · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• A61K38/05

  Dipeptides · CPC title

• A61K31/706

  containing six-membered rings with nitrogen as a ring hetero atom · CPC title